Now Playing
Opinion|Videos|March 21, 2024
Patient Scenario: A 63-Year-Old Man with Multiple Myeloma
A panel of experts on multiple myeloma review a patient profile, offer their initial impressions, and highlight the role of an advanced practice provider.
Advertisement
Episodes in this series
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
Sacituzumab Govitecan Efficacy, Safety Debated in First-Line Metastatic TNBC
3
FDA Sets PDUFA Date for Rivoceranib/Camrelizumab Resubmission After Third CRL in Unresectable HCC
4
Where Does Prostate Brachytherapy Fit Best in the Treatment Paradigm?
5